KYMR - Kymera announces expansion of KT-474 HS and AD phase 2 studies
2024-07-08 16:17:01 ET
More on Kymera Therapeutics, Sanofi, etc.
- Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting
- Sanofi: A Leader In Life-Saving Vaccines And Treatments
- Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
- Sanofi, Regeneron win EU label expansion for Dupixent in COPD
- Vigil Neuroscience jumps 34% as Sanofi invests $40M